496 related articles for article (PubMed ID: 26859368)
41. A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.
Koike H; Nishi R; Yagi S; Furukawa S; Fukami Y; Iijima M; Katsuno M
Adv Ther; 2023 Jan; 40(1):25-40. PubMed ID: 36152266
[TBL] [Abstract][Full Text] [Related]
42. The Role of T Helper Type 2 (Th2) Cytokines in the Pathogenesis of Eosinophilic Granulomatosis with Polyangiitis (eGPA): an Illustrative Case and Discussion.
Milne ME; Kimball J; Tarrant TK; Al-Rohil RN; Leverenz DL
Curr Allergy Asthma Rep; 2022 Nov; 22(11):141-150. PubMed ID: 36103081
[TBL] [Abstract][Full Text] [Related]
43. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
Front Immunol; 2020; 11():593748. PubMed ID: 33488590
[TBL] [Abstract][Full Text] [Related]
44. The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.
Kouverianos I; Angelopoulos A; Daoussis D
Rheumatol Int; 2023 Jul; 43(7):1245-1252. PubMed ID: 37085573
[TBL] [Abstract][Full Text] [Related]
45. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
46. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
Matsuno O; Minamoto S
Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
[TBL] [Abstract][Full Text] [Related]
47. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
Sridhar S; Liu H; Pham TH; Damera G; Newbold P
Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
[TBL] [Abstract][Full Text] [Related]
48. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
[TBL] [Abstract][Full Text] [Related]
49. Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab.
Chica-Guzmán MV; Morillo-Guerrero R; Carrón-Herrero A; González-de-Olano D; Almonacid-Sánchez C
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):228-230. PubMed ID: 32407950
[No Abstract] [Full Text] [Related]
50. Benralizumab for the treatment of asthma.
Saco TV; Pepper AN; Lockey RF
Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
[TBL] [Abstract][Full Text] [Related]
51. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
52. Eosinophils, the IL-5/IL-5Rα axis, and the biologic effects of benralizumab in severe asthma.
Matucci A; Maggi E; Vultaggio A
Respir Med; 2019; 160():105819. PubMed ID: 31734469
[TBL] [Abstract][Full Text] [Related]
53. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
Walsh GM
Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
[TBL] [Abstract][Full Text] [Related]
54. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
[TBL] [Abstract][Full Text] [Related]
55. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
Bakakos A; Rovina N; Bakakos P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
[TBL] [Abstract][Full Text] [Related]
56. Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
Son H; Lee WJ; Moon J; Yoon S; Jung KH; Park KI; Lee SK; Chu K
J Neuroimmunol; 2021 Jun; 355():577551. PubMed ID: 33773378
[TBL] [Abstract][Full Text] [Related]
57. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
[TBL] [Abstract][Full Text] [Related]
58. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
[TBL] [Abstract][Full Text] [Related]
59. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
60. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
